United Therapeutics Corporation (UTHR)
NASDAQ · Healthcare · Biotechnology
Profile
United Therapeutics Corporation
- Exchange
- NASDAQ
- Ticker
- UTHR
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Key facts
United Therapeutics Corporation: key facts
- United Therapeutics Corporation (NASDAQ: UTHR) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, United Therapeutics Corporation reported revenue of $3.2B and net income of $1.3B.
- Revenue grew 17.2% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $3.2B and net income was $1.3B.
MonkScore
United Therapeutics Corporation's MonkScore
MonkScore
MonkScore range: 40–50
as of October 2026
Sector rank: 389 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth40–50
- Profitability80–90
- Quality20–30
- Market Conviction30–40
- Safety40–50
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
United Therapeutics Corporation's annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B |
| Gross profit | $2.7B | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B |
| Operating income | $1.4B | $1.5B | $1.4B | $1.2B | $979.7M | $555.9M |
| Net income | $1.3B | $1.3B | $1.2B | $984.8M | $727.3M | $475.8M |
| Operating cash flow | $1.7B | $1.6B | $1.3B | $978.0M | $802.5M | $598.2M |
| Capital expenditure | -$592.2M | -$520.5M | -$246.5M | -$230.4M | -$138.8M | -$120.8M |
| Free cash flow | $1.1B | $1.0B | $1.1B | $747.6M | $663.7M | $477.4M |
| Total debt | $0.0 | $37.6M | $300.0M | $700.0M | $800.0M | $800.0M |
| Cash | $1.8B | $1.6B | $1.7B | $1.2B | $961.2M | $894.8M |
Revenue growth a year
- 1-year
- 10.6%
- 3-year
- 18.0%
- 4-year
- 17.2%
Compound growth between fiscal years.
Peers
Similar companies
- ACADIA Pharmaceuticals Inc.NASDAQ:ACADMonkScore range: 40–50
- Gyre Therapeutics, Inc.NASDAQ:GYREMonkScore range: 40–50
- Ginkgo Bioworks Holdings, Inc.NYSE:DNAMonkScore range: 40–50
- Janux Therapeutics, Inc.NASDAQ:JANXMonkScore range: 40–50
- Geron CorporationNASDAQ:GERNMonkScore range: 50–60
- Vir Biotechnology, Inc.NASDAQ:VIRMonkScore range: 50–60
- Moderna, Inc.NASDAQ:MRNAMonkScore range: 50–60
- Dianthus Therapeutics, Inc.NASDAQ:DNTHMonkScore range: 50–60
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.